Mike Bodkin joins Drug Discovery Unit

Mike brings with him a wealth of experience in computational approaches for drug discovery gained within Pharma. He has an ambition to converge biology, chemistry, and data sciences to expedite the discovery of novel therapeutics using state-of-the-art in silico approaches.

Mike did his PhD in the crystallography department at Birkbeck and a post-doc in the pharmacology department at Cambridge. He began his career in medicinal chemistry at Roche and the James Black Foundation before moving into computational chemistry at AstraZeneca and Eli Lilly. In 2014 he moved to Evotec as an executive vice president where he built the in silico R&D department to integrate AI developers, computational chemistry, bioinformaticians, and data scientists to enable AI-driven drug discovery.